title: A less costly regimen of alglucerase to treat Gaucher's disease.
abstract: BACKGROUND
  Alglucerase (Ceredase) provides effective enzyme-replacement treatment for patients with Gaucher's disease, but at the usually recommended dose of 60 U per kilogram of body weight every two weeks (130 U per kilogram per month), it costs $382,200 per year for a 70-kg patient. Theoretical considerations suggest that more frequent administration would be more efficient.
  
  
  METHODS
  Fourteen patients with type 1 Gaucher's disease that was moderately severe to severe were given 30 U of alglucerase per kilogram per month, in divided doses given either daily or three times weekly, or 120 U given three times weekly. The effect of the treatment on the size of the liver and spleen and on blood counts was compared with published data on patients who received a total dose four to five times as large as the lower dose we used and who received treatment every two weeks.
  
  
  RESULTS
  The response to 30 U of alglucerase per kilogram per month, fractionated into three or seven doses weekly, was approximately the same as that reported after the administration every two weeks of a dose four or five times as large, given in the large infusions usually recommended. A fourfold increase in the dose given three times weekly, from 2.3 to 9.2 U per kilogram, did not substantially increase the rate of improvement.
  
  
  CONCLUSIONS
  The treatment of Gaucher's disease with smaller total doses of alglucerase given more frequently yields satisfactory results. A dose of 2.3 U per kilogram three times weekly yields major financial benefits with no sacrifice of therapeutic effect. Even taking into account the increased ancillary costs of more frequent administration, this method of administering alglucerase reduces the annual cost of the drug for a 70-kg patient to about $100,000.
authors.affiliation: Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037.
authors.forename: M L
authors.initials: ML
authors.lastname: Figueroa
authors.forename: B E
authors.initials: BE
authors.lastname: Rosenbloom
authors.forename: A C
authors.initials: AC
authors.lastname: Kay
authors.forename: P
authors.initials: P
authors.lastname: Garver
authors.forename: D W
authors.initials: DW
authors.lastname: Thurston
authors.forename: J A
authors.initials: JA
authors.lastname: Koziol
authors.forename: T
authors.initials: T
authors.lastname: Gelbart
authors.forename: E
authors.initials: E
authors.lastname: Beutler
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002648:Child; D004334:Drug Administration Schedule; D016527:Drug Costs; D005776:Gaucher Disease / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D013154:Spleen / Q000187:drug effects / Q000473:pathology
chemical_list: C070292:alglucerase; D005962:Glucosylceramidase